Эффективность длительной терапии ингибиторами холинэстеразы у больных деменцией с тельцами Леви
Диссертация
Также, в лечении ДТЛ могут использоваться агонисты ЫМЮА-рецепторов (в частности, мемантин), терапевтический эффект которого возможно связан не только с действием на ЫУОА-рецепторы, но и с его влиянием на высвобождение дофамина в префронтальной коре, с возможным опосредованным действием через глутаматергическую медиаторную систему на другие медиаторные системы головного мозга, а также… Читать ещё >
Содержание
- Список сокращений
- ГЛАВА 1. Обзор литературы
- 1. 1. Морфология и патогенез ДТЛ
- 1. 2. Клиническая картина ДТЛ
- 1. 3. Диагностика и наблюдение больных ДТЛ
- 1. 4. Нейрохимические нарушения
- 1. 5. Лечение ДТЛ
- 1. 5. 1. Ингибиторы холинэстеразы
- 1. 5. 2. Модулятор глутаматных рецепторов NMDA-типа
- 2. 1. Клиническая характеристика обследованных пациентов
- 2. 2. Методы исследования
- 3. 1. Клинико — неврологическая характеристика больных
- 3. 1. 1. Оценка когнитивных нарушений
- 3. 1. 2. Оценка нейропсихиатрических нарушений
- 3. 1. 3. Оценка симптома паркинсонизма
- 3. 1. 4. Оценка вегетативных нарушений
- 3. 2. Оценка факторов, влияющих на клиническую картину ДТЛ
- 3. 3. Регрессионный анализ значимости факторов риска
- 3. 4. Ретроспективная оценка групп (шкала IQCODE)
- 3. 5. Оценка динамики когнитивных функций на фоне терапии de 67 novo
- 3. 5. 1. Динамика общей оценки
- 3. 5. 2. Динамика оценки по когнитивным субшкалам
- 3. 6. Оценка предикторов эффективности терапии
- 3. 7. Оценка эффективности лечения при исходной терапии более 76 года
- 3. 8. Оценка комбинированной терапии
- 3. 9. Оценка влияния препаратов леводопы и нейролептиков на 77 эффективность ИХЭ
- 3. 10. Оценка безопасности и переносимости терапии ИХЭ
Список литературы
- Андросова Л.В., Селезнева Н. Д. Акатинол мемантин при болезни Альцгеймера: клинико-иммунологические корреляции. //Ж. невролог, и психиатр. -2000. -Т. 100, № 9. -С.36−38.
- Антоненко Л.М. Особенности поддержания равновесия и ходьбы у пожилых больных с болезнью Паркинсона, прогрессирующим надъядерным параличем и мултисистемной атрофией. Дисс.канд.мед.наук. -М., 2004.
- Артемьев Д.В. Возрастные особенности болезни Паркинсона.//Дисс. канд. мед. наук. -ML, 1995. 138 с.
- В.В. Захаров, H.H. Яхно. Нарушения памяти. Москва. — «Гэотар-Мед». — 2003. — 160 с.
- Вейн A.M., Голубев В. Л., Яхно H.H. Роль нарушений «неспецифических» систем мозга в патогенезе паркинсонизма.//Ж. невропатологии и психиатрии им. С. С. Корсакова. 1975. — Т. 5. — № 7. — С. 970−975.
- Гаврилова С.И. Фармакотерапия болезни Альцгеймера.//М., издательство «Пульс». -2003. -319 с.
- Гнездицкий В.В. Вызванные потенциалы мозга в клинической практике. Таганрог: издательство ТРТУ — 1997.
- Голубев B. J1., Левин Я. И., Шамликашвили Ц. А. Латерализованные формы паркинсонизма (клинические, электрофизиологические и психомоторные аспекты).//Ж. невропатологии и психиатрии им. С. С. Корсакова. 1989. — Т. 89. — № ц.с. 119−123.
- Дамулин И.В. Болезнь Альцгеймера и сосудистая деменция. Москва, 2002. — 85 с.
- Дамулин И.В. Новая нейропротективная и терапевтическая стратегия при деменциях: антагонист NMDA-рецепторов Акатинол Мемантин. //Русск. мед. журн. -2001. -Т.9, № 25. -С. 1178−1182.
- Дамулин И.В., Жученко Т. Д., Левин О. С. Нарушения равновесия и походки у пожилых.//В кн. Достижения в нейрогериатрии.//Под ред. H.H. Яхно, И. В. Дамулина. М., ММА. — 1995. — с. 71−97.
- Захаров В.В. Нарушение когнитивных функций при болезни Паркинсона и симптоматическом паркинсонизме.//Дисс. докт. мед. наук. -М., 2003.-332 с.
- Захаров В.В. Нарушение мнестической функции при идиопатическом паркинсонизме .//Дисс. канд. мед. наук. -М., 1997. 141 с.
- Захаров В.В., А.Б. Локшина. Деменция с тельцами Леви: клиника, патологические проявления, лечение.//Неврологический журнал. 1998. -Т.З.-№ 5.-С. 57−61.
- Захаров В.В., Ахутина Т. В., Яхно H.H. Нарушение памяти при болезни Паркинсона.//Ж. невропатологии и психиатрии. 1999. — Т. 99. — №. 4. — С. 1722.
- Захаров В.В., Дамулин ИВ., Яхно H.H. Медикаментозная терапия деменций.//Клиническая фармакология и терапия. 1994. — Т. 3. — № 4. — С. 69−75.
- Захаров В.В., Хатиашвили И. Т., Яхно H.H. Деменция с тельцами Леви.//Неврологический журнал. 1998. — Т. 3. — № 6. — С. 7−10.
- Зенков Л.Р. Патофизиологические механизмы паркинсонизма в свете общего системного подхода // Паркинсонизм (вопросы клиники, патогенеза и лечения). Труды 1 ММИ, — 1974, — С. 66−89.
- Зенков Л.Р., Елкин М. Н., Медведев Г. А. Клиническая нейрофизиология нейрогериатрических расстройств // Достижения в нейрогериатрии. М., 1995. 4.2. 160с.
- Коберская H.H. Клинико-электрофизиологические характеристики когнитивных нарушений при болезни Паркинсона и симптоматическом паркинсонизме.//Дисс. канд. мед. наук. М., 2003. — 147 с.
- КорсаковаНК., Московичюте Л. И. Подкорковые структуры мозга и психические процессы.-М. Издательство МГУ-1985. 257 с.
- Коршунов A.M. Синдром брадикардии блока проведения -ортостатической гипотонии у больных с паркинсонизмом при приеме дофаминовых агонистов.//Неврологический журнал. — 1998. — № 6. — с.36−39.
- Левин О.С. Клинико-нейропсихологические и нейровизуализационные аспекты дифференциальной диагностики паркинсонизма. Дисс.докт.мед.наук. -М., 2003.
- Левин О.С. Механизм регуляции движений и патогенез основных экстрапирамидных синдромов. // В кн.: Экстрапирамидные расстройства:
- Руководство по диагностике и лечению./Под ред. В. Н. Штока, И. АИвановой-Смоленской, О. С. Левина. -М.: МЕДпресс-информ, 2002. С. 16−55.
- Левин О.С., Амосова H.A., Наймушина Т. В., Смоленцева И. Г. Сравнительное исследование болезни Паркинсона и деменции с тельцами Леви.//Ж невропатологии и психиатрии им. С. С. Корсакова. 2004. — Т. 104. -№ 1.-С. 3−10.
- Левин О.С., Наймушина Т. В., Смоленцева И. Г. Психотические расстройства при болезни Паркинсона:клиниконейропсихологическое исследование.//Неврологический журнал. 2002. — № 5.-е. 21−29.
- Левин Я.И. Клиническая сомнология проблемы и решения.//Неврологический журнал. — 2004. — № 4. — с. 4−13.
- Лурия А.Р. Нейропсихология памяти. Нарушение памяти при глубинных поражениях мозга.//М., Педагогика. — 1976.
- Лурия А.Р. Нейропсихология памяти. Нарушение памяти при локальных поражениях мозга.//М., Педагогика. 1974.
- Медведев И.О. Исследование эффектов антагонистов NMDA-рецепторов на экспериментальных моделях хронической боли и опиатной зависимости. Автореф. дисс.. канд. мед. наук. -С.-Пб., 2001. -24 с.
- МхитарянЭ.А. Значение сосудистых церебральных нарушений при болезни Альцгеймера.// Дисс. канд. мед. наук. -М&bdquo- 2004. 129 с.
- С.Н. Иллариошкин. Конформационные болезни мозга. Москва. -«Янус-К». — 2002. — 246 с.
- Струценко А.А. Двигательные и вегетативные нарушения при деменции с тельцами Леви и болезни Паркинсона.//Дисс. канд. мед. наук. -М., 2004. 132 с.
- Толкунов Б.Ф. Стриатум и сенсорная специализация нейронной сети.//Ленинград. Издательство «Наука». — 1978. — 178 с.
- Хатиашвили И.Т. Сравнительная характеристика двигательных и вегетативных нарушений при прогрессирующем надъядерном параличе, множественной системной атрофии и болезни Паркинсона.//Дисс. канд. мед. наук. М., 2001.- 152 с.
- Хатиашвили И.Т., Яхно Н. Н. Клиническая оценка глазодвигательных нарушений при паркинсонизме.//Неврологический журнал. 2000. — № 1.-е. 27−31.
- Янакаева Т.А. Сравнительный анализ когнитивных и аффективных расстройств при дисциркуляторной энцефалопатии и болезни Паркинсона.//Дисс. канд. мед. наук. -М., 1999. 135 с.
- Aarsland D, Bronnick К, Karlsen К: Donepezil for dementia with Lewy bodies: a case study. Int J Geriatr Psychiatry 1999- 14:69−74
- Aarsland D., Larsen J.P., Cummings J.L., Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease. A community-based study .//Arch. Neurol. 1999.-V. 56.-P. 595−601.
- Albin R.L., Minoshima S., D’Amato C.J., et al. Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease.// Neurology. 1996. — V. 47. -P. 462−466.
- Albin R.L., Minoshima S., Kuhl D.A., Sima A. A. Fluoro-deoxyglucose positron emission tomography in Lewy body disease compared with Alzheimer’s disease.//Neurology. 1998.-V. 62.-P. 421−426.
- Alhainen K, Riekkinen PJ: Discrimination of Alzheimer patients responding to cholinesterase inhibitor therapy. Acta Neurol Scand Suppl 1993- 149:16−21
- Ambrozi L., Danielczyk W. Treatment of impaired cerebral function in psychogeriatric patients with memantine: results of a phase II double-blind study. //Pharmacopsychiatry. -1998. -Vol.21. -P. 144−146.
- Anon. Biography of Lewy .//Archives of Neurology and Psychiatry. Chicago. — 1951.-V. 66.-P. 114−115.
- Arvanov V.L., Chou H.C., Chen R.C., Tsai M.C. Pre- and post-synaptic actions of memantine at cholinergic central synapse of achatina fulica. //Сотр. Biochem. Physiol. 1994. -V. 107. -P.305−311.
- Asenbaum S., Pirker W., Angelberger P., et al. 123Ibeta-CIT and SPECT in essential tremor and Parkinson’s disease.// J. Neural. Transm. 1998. — V. 105. — P. 1213−1228.
- Bacanu S.A., Devlin B., Chowdari R.V., et al. Linkage analysis of Alzheimer disease with psychosis.//Neurology. 2002. -V. 59. — P. 118−120.
- Bachurin S., Tkachenko S., Baskin I. et al. Neuroprotective and cognition-enhancing properties of MK-801 flexible analogs. Structure-activity relationships. //Ann. N. Y. Acad. Sci. -2001. -Vol.939. -P.219−236.
- Bacskai B.J., Klunk W.E., Mathis C.A., et al. Imaging amyloid-beta deposits in vivo.// J. Cereb. Blood. Flow. Metab. 2002. — V. 22. — P. 1035−1041.
- Ballard C, Grace J, McKeith I, et al: Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer’s disease. Lancet 1998- 351:1032−1033
- Ballard C, O’Brien J, Barber B, et al: Neurocardiovascular instability, hypotensive episodes, and MRI lesions in neurodegenerative dementia. Ann NY Acad Sci 2000- 903:44245
- Ballard C, Piggott M, Johnson M, et al: Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Ann Neurol 2000- 48:868−876
- Ballard C., Bannister C., Graham C., et al. Associations of psychotic symptoms in dementia sufferers.// The British Journal of Psychiatry. 1995. — V. 167. — P. 537−540.
- Ballard C., Holmes C., McKeith I., et al. Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer’s disease.// Am. J. Psychiatry. 1999. — V. 156. — P. 1039−1045.
- Ballard C., O’Brien J., Tovee M. Qualitative performance characteristics differentiate dementia with Lewy bodies and Alzheimer’s disease.// J. Neurol. Neurosurg. Psychiatry. -2002.-V. 72.-P. 565−566.
- Ballard C.G., Aarsland D., McKeith I., et al. Fluctuations in attention: PD dementia vs DLB with parkinsonism.// Neurology. 2002. — V. 59. — N. 11. — P. 1714- 1720.
- Barber R, Gholkar A, Scheltens P, et al: MRI volumetric correlates of white matter lesions in dementia with Lewy bodies and Alzheimer’s disease. Int J Geriatr Psychiatry 2000- 15:911−916CrossRef. Medline]
- Barber R, Scheltens P, Gholkar A, et al: White matter lesions on magnetic resonance imaging in dementia with Lewy bodies, Alzheimer’s disease, vascular dementia, and normal aging. J Neurol Neurosurg Psychiatry 1999- 67:66−72
- Barber R., Scheltens P., Gholkar A., et al. White matter lesions on magnetic resonance imaging in dementia with Lewy bodies, Alzheimer’s disease, vascular dementia, and normal aging.// J. Neurol. Neurosurg. Psychiatry. 1999. — V. 67. -P. 66−72.
- Barker R.A., Foltynie T. How common is dementia with Lewy bodies?// J. Neurol. Neurosurg. y and Psychiatry. 2003. — V. 74. — P. 697−698.
- Barker R.A. Getting to the heart of dementia.// J. Neurol. Neurosurg. Psychiatry. 2001. -V. 71 — P. 574−575.
- Benamer T.S., Patterson J., Grosset D.G., et al. Accurate differentiation of parkinsonism
- Benarroch E.E., Schmeichel A.M., Parisi J.E. Involvement of the ventrolateral medulla in parkinsonism with autonomic failure.//Neurology. 2000. — V. 54. — P. 963−968.
- Benton A.L., Varney N.R., Hamsher K. Visuospatial judjement. A clinical test.//Arch. Neurol. 1978. — V. 35. — P. 364−367.
- Berg E. A. A simple objective test for measuring flexibility in thinking.//J. Ger. Psychol. 1948.-V. 39.-P. 15−22.
- Berr C., Richard M.-J., Gourlet V., Favier A. Oxidative stress, enzymatic activities and cognitive decline in the EVA Study. //Neurobiol. Aging. -2000. -Vol.21, N. IS. -P.S64.
- Bigler E.D., Lowry C.M., Anderson C.V., et al. Dementia, quantitative neuroimaging, and apolipoprotein E genotype.// Am. J. Neuroradiol. 2000. — V. 21. — P. 1857−1868.
- Bitsios P., Prettyman R., Szabadi E. Changes in autonomic function with age: a study of pupillary kinetics in healthy young and old people.// Age and Ageing. 1996. — V. 25. — P. 432−438.
- Bodis-Wollner I. Visual deficits related to dopamine deficiency in experimental animals and Parkinson’s disease patients. Review.// Trends Neurosci. 1990. — V. 13. — P. 296 302.
- Bonnet A.M., Pichon J., Vidailhet M., et al. Urinary disturbances in striatonigral degeneration and Parkinson’s disease: clinical and urodynamic aspects.//Mov Disord. 1997.-V. 12.-P. 509−513.
- Booij J., Tissingh G., Boer G.J., et al. 123IFP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson’s disease.// J. Neurol. Neurosurg. Psychiatry. 1997. — V. 62. -P. 133−140.
- Bordet R., Benhadjali J., Destee A., et al. Sympathetic skin response and R-R interval variability in multiple system atrophy and idiopathic Parkinson’s disease. Mov Disord. 1996. — V. 1 l.-P. 268−272.
- Bouman W.P., Pinner G. Use of atypical antipsychotic drugs in old age psychiatry.// Advances in Psychiatric Treatment. 2002. — V. 8. P. 49−58.
- Bozeat S., Lambon Ralph M.A., Patterson K., et al. Non-verbal semantic impairment in semantic dementia.// Cognitive Neuropsychology 2000. — V. 17. -P. 437−466.
- Bradley R.M., O’Sullivan V.T., Soper N.D.W., et al. Cerebral perfusion SPET correlated with Braak pathological stage in Alzheimer’s disease.// Brain. -2002. V. 125. — N. 8. — P. 1772−1781.
- Brooks D.J. Diagnosis and managements of atypical parkinsonian syndromes.//J. Neurol. Neurosurg. Psychiatry. 2002. — V. 72. — Suppl. 1. — p. 110 116.
- Buldyrev S., Cruz L., Gomez-Isla T.// Description of microcolumnar ensembles in association cortex and their disruption in Alzheimer and Lewy body dementias.// Proc. Natl. Acad. Sci. -2000. V. 97. — P. 5039−5043.
- Burke WJ, Pfeiffer RF, McComb RD: Neuroleptic sensitivity to clozapine in dementia with Lewy bodies. J Neuropsychiatry Clin Neurosci 1998- 10:227−229
- Burkhardt C.R., Filley C.M., Kleinschmidt-DeMasters B.K., et al. Diffuse Lewy body disease and progressive dementia.//Neurology. 1988. -V. 38. — P. 1520−1528.
- Burn D. Parkinsonism in DLB and PDD.// Third International Workshop on Dementia with Lewy bodies and Parkinson’s disease dementia (DLB/PDD). -Conference Handbook.-2003.-P. 124.
- Burns A., Luthert P., Levy R., et al. Accuracy of clinical diagnosis of Alzheimer’s disease.//BMJ. 1990. -V. 301. — P. 1026.
- Buysse DJ, Reynolds CF III, Monk TH, et al: The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989- 28:193−213
- Byrne E.J., Lennox G., Lowe J., et al. Diffuse Lewy body disease: clinical features in 15 cases.// J. Neurol. Neurosurg. Psychiatry. 1989. — V. 52. — P. 709 717.
- Calderon M., Perry R.J., Erzinclioglu S.W., et al. Perception, attention, and working memory are disproportionately impaired in dementia with Lewy bodies compared with Alzheimer’s disease.//J. Neurol. Neurosurg. Psychiatry 2001. -V. 70.-P. 157−164.
- Cercy S.P., Bylsma F.W. Lewy bodies and progressive dementia: a critical review and meta-analysis.// Int. Neuropsychol. Soc. 1997. -V. 3. — P. 179−194.
- Chan S.L., Lu C., Mattson M.P. Modification of cysteine proteases and AMP A receptor subunits by the lipid peroxidation product 4-hydroxynonenal: Impact on neuronal apoptosis and necrosis. //Neurobiol. Aging. -2000. -Vol.21, N. IS.-P.S17.
- Chen R., Kumar S., Garg R.R., et al. Impairment of motor cortex activation and deactivation in Parkinson’s disease.// Clin. Neurophysiol. 2001. — V. 112. — N. 4. — P. 600−607.
- Choi P. Co-association of parkin and alpha-synuclein.// Neuroreport.- 2001. V. 12. — P. 2839−2843.
- Clarke N.A., Williams A.J., Kopelman M.D. Rapid eye movement sleep behaviour disorder, depression and cognitive impairment.// The British Journal of Psychiatry. 2000.-V. 176.-P. 189−192.
- Clegg A., Bryant J., Nicholson T., et al. Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer’s disease. A systematic review.// Int J Technol Assess Health Care. 2002. — V. 18. — P. 497−507.
- Cohen I., Magai C. Racial Differences in Neuropsychiatric Symptoms Among Dementia Outpatients.// Am. J. Geriatr. Psychiatry. 1999. — V. 7. -N. 1. -P. 57−63.
- Cohen-Mansfield J, Marx MS, Rosenthal AS: A description of agitation in a nursing home. J Gerontol 1989- 44: M77-M84
- Connor D.J., Salmon D.P., Sandy T.J., et al. Cognitive profiles of autopsy-confirmed Lewy body variant v pure Alzheimer’s disease.// Arch. Neurol. 1998. -V. 55.-P. 9 941 000.
- Corey-Bloom J., Thai L., Galasko D., et al. Diagnosis and evaluation of dementia.//Neurology. 1995. -V. 45. — P. 211−218.
- Cornelia C.L., Tanner C.M., Ristanovic R.K. Polysomnographic sleep measures in Parkinson’s disease patients with treatment-induced hallucinations.// Ann. Neurol. 1993.-V. 34.-P. 710−714.
- Coulson BS, Fenner SG, Almeida OP: Successful treatment of behavioural problems in dementia using a cholinesterase inhibitor: the ethical questions. Aust NZ J Psychiatry 2002- 36:259−262
- Cowburn R., Hardy J., Roberts P., Briggs R. Presynaptic and postsynaptic glutamatergic function in Alzheimer’s disease. //Neurosci. Lett. -1988. -Vol.86. -P. 109 113.
- Cummings JL, Mega M, Gray K, et al: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994- 44:2308−2314
- Dalrymple-Alford J. Comparative neuropsychology of Lewy body and Alzheimer’s dementia.// J Neurol Neurosurg Psychiatry 2001. V. 70. — P. 148 153.
- Danysz W., Parsons C.G., Mobius H.-J. et al. Neuroprotective and synptomatological action of memantine relevant for Alzheimer’s disease A unified glutamatergic hypothesis on the mechanism of action. //Neurotox. Res. -2000. -Vol.2. — P.85−97.
- De la Torre J.C. Alzheimer Disease as a Vascular Disorder./' Stroke -. 2002. V. 33.-P. 1152−1153.
- De La Torre J.C. Vascular Basis of Alzheimer’s Pathogenesis.// Annals of the New York Academy of Sciences. 2002. — V. 977. — V. 196−215.
- De Marinis M., Stocchi F., Gregori B., et al. Sympathetic skin response and cardiovascular autonomic function tests in Parkinson’s disease and multiple system atrophy with autonomic failure.//Mov. Disord. 2000. — V. 15. — P. 1215−1220.
- De Vos R.A., Jansen E.N., Stam F.C., et al. «Lewy body disease»: clinico-pathological correlations in 18 consecutive cases of Parkinson’s disease with and without dementia.// Clin. Neurol. Neurosurg. 1995. — V. 97. — P. 13−22.
- Denson M.A., Wszolek Z.K., Pfeiffer R.F., et al./Familial parkinsonism, dementia, and Lewy body disease: study of family G.//Ann. Neurol.-1997.-V. 42. -N. 4.-P. 638−643.
- Eagger S, Levy R, Sahakian B: Tacrine in Alzheimer’s disease. Lancet 1991- 337:989−992
- Fahn S, Elton RL (UPDRS Development Committee): Unified Parkinson’s Disease Rating Scale, in Recent Developments in Parkinson’s Disease. Edited by Fahn S, Marsden CD, Goldstein M. New York, Macmillan, 1987, pp 153−163
- Farlow M, Gracon SI, Hershey LA, et al: A controlled trial of tacrine in Alzheimer’s disease. JAMA 1992- 268:2523−2529
- Fergusson E, Howard R: Donepezil for the treatment of psychosis in dementia with Lewy bodies. Int J Geriatr Psychiatry 2000- 15:280−281
- Folstein MF, Folstein SE, McHugh PR: «Mini-Mental State»: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975- 12:189−198
- Geizer M, Ancill RJ: Combination of risperidone and donepezil in Lewy body dementia. Can J Psychiatry 1998- 43:421−422
- Giacobini E, Zhu XD, Williams E, et al: The effect of the selective reversible acetylcholinesterase inhibitor E2020 on extracellular acetylcholine and biogenic amine levels in rat cortex. Neuropharmacology 1996- 35:205−211
- Grace J, Daniel S, Stevens T, et al: Long-term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial. Int Psychogeriatr 2001- 13:199−205
- Grace JB, Walker MP, McKeith IG: A comparison of sleep profiles in patients with dementia with Lewy bodies and Alzheimer’s disease. Int J Geriatr Psychiatry 2000- 15:1028−1033
- Hoehn MM, Yahr MD: Parkinsonism: onset, progression and mortality. Neurology 1967- 17:427−442
- Johns MW: Daytime sleepiness, snoring, and obstructive sleep apnea: the Epworth Sleepiness Scale. Chest 1993- 103:30−36
- Kaufer DI, Catt KE, Lopez OL, et al: Dementia with Lewy bodies: response of delirium-like features to donepezil. Neurology 1998- 51:1512
- Knapp M, Knopman DS, Solomon PR, et al: A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease. JAMA 1994- 271:985−991
- Lanctot KL, Herrmann N: Donepezil for behavioural disorders associated with Lewy bodies: a case series. Int J Geriatr Psychiatry 2000- 15:338−345
- Lawton MP, Brody EM: Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969- 9:179−186
- Lebert F, Pasquier F, Souliez L, et al: Tacrine efficacy in Lewy body dementia. Int J Geriatr Psychiatry 1998- 13:516−519
- Levy R, Eagger S, Griffiths M, et al: Lewy bodies and response to tacrine in Alzheimer’s disease (letter). Lancet 1994- 343:176
- Lezak M.D. Neuropsychology assessment.//NY University Press. 1983. -P. 768.
- Lindeboom J" Schmand B., Tulner L., et al. Visual association test to detect early dementia of the Alzheimer type.// J. Neurol. Neurosurg. Psychiatry. 2002. -V. 73.-P. 126−133.
- Lippa C.F., Smith T.W., Nee L., et al. Familial Alzheimer’s disease and cortical Lewy bodies: is there a genetic susceptibility factor?//Dementia. -1995. -V. 6.-N. 4.-P. 191−194.
- Livingstone G., Katona C. How useful are Cholinesterase inhibitors in the treatment of Alzheimer’s disease? A number needed to treat analysis.// Int. J. Geriatr. Psychiatry. 2000. — V. 15. — P. 203−207.
- Lobotesis K., Fenwick J.D., Phipps A., et al. Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD.//Neurology. 2001. — V. 56. -P. 643−649.
- Lopez O.L., Hamilton R.L., Becker J.T., et al. Severity of cognitive impairment and the clinical diagnosis of AD with Lewy bodies.//Neurology. -2000. -V. 54. P. 1780−1787.
- Lopez O.L., Litvan I., Catt K.E., et al. Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias.// Neurology. 1999. — V. 53.-P. 1292−1299.
- Lopez O.L., Wisniewski S., Hamilton R.L., et al. Predictors of progression in patients with AD and Lewy bodies.//Neurology. 2000. — V. 54. — P. 1774−1779.
- Luis C.A., Barker W.W., Gajaraj K., et al. Sensitivity and specificity of three clinical criteria for dementia with Lewy bodies in an autopsy-verified sample.// Int. J. Geriatr. Psychiatry. 1999. — V. 14. — P. 526−533.
- Maclean LE, Collins CC, Byrne EJ: Dementia with Lewy bodies treated with rivastigmine: effects on cognition, neuropsychiatrie symptoms, and sleep. Int Psychogeriatr 2001 — 13:277−288
- Maltby N, Broe GA, Creasey H, et al: Efficacy of tacrine and lecithin in mild to moderate Alzheimer’s disease: double blind trial. BMJ 1994- 308:879−883
- Mann D. Anosmia in dementia is associated with Lewy bodies rather than Alzheimer’s pathology.// J. Neurol. Neurosurg. Psychiatry. 2001. — V. 70. — P. 720−721.
- Mao J. NMDA and opioid receptors: their interactions in antinociception, tolerance and neuroplasticity. //Brain Res. Rev. -1999. -Vol.30. -P.289−304.
- Marek K.L., Seibyl J.P., Zoghbi S.S., et al. 123Ibeta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease.// Neurology. 1996. — V. 46. — P. 231−237.
- Mark L.P., Prost R.W., Ulmer J.L. et al. Pictorial review of glutamate excitotoxicity: Fundamental concepts for neuroimaging. //Amer. J. Neuroradiol. -2001.-Vol.22.-P. 1813−1824.
- Martinoli M.G., Trojanowski J.Q., Schmidt M.L., et al. Association of apolipoprotein epsilon 4 allele and neuropathologic findings in patients with dementia.//Acta Neuropathol. Berl. -1995. -V. 90. -N. 3. -P. 239−243.
- Mattis S. Mental status examination for organic mental syndrome in the elderly patients.//In: Ger Psychiatry. L. Bellack and T.B. Karasu (eds). — NY: Gryne and Straton. — 1976.
- Mattis S: Dementia Rating Scale: Professional Manual. Odessa, Fla, Psychological Assessment Resources, 1988
- Mayeux R., Foster N.L., Rossor M., Whitehouse P.J. The clinical evaluation of patients with dementia.// In: Whitehouse PJ, ed. Dementia. Vol. 40 of Contemporary neurology series. Philadelphia: F.A. Davis. — 1993. — P. 92−129.
- Mayeux R., Sano M. Treatment of Alzheimer’s disease.// N. Engl. J. Med. --V. 341.-P. 1670−1679.
- Mayeux R., Saunders A.M., Shea S., et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer’s disease.//N. Engl. J. Med. 1998. — V. 338. — P. 506−511. Erratum, N Engl J Med 1998−338:1325.
- Mc Keith I., Fairbairn A.F., Bothwell R.A., et al. An evaluation of the predictive validity and inter-rater reliability of clinical diagnostic criteria for senile dementia of Lewy body type.//Neurology. -1994. -V. 44. -N. 5. -P. 872−877.
- Mc Keith I., Galasko D., Kosaka K., et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop.//Neurology. -1996. -V. 47. -N. 5. -P. 1113−1124.
- Mc Shane R., Gedling K., Reading M., et al. Prospective study of relations between cortical Lewy bodies, poor eyesight, and hallucinations in Alzheimer’s disease.//! Neurol. Neurosurg. Psychiatry. -1995. -V. 59. -N. 2. -P. 185−188.
- McKeith I. Dementia with Lewy bodies.//Br. J. Psychiatry. 2002. — V. 180.-N. 2.-P. 144- 147.
- McKeith I., Ballard C.G., Perry R.H., et al. Prospective validation of Consensus criteria for the diagnosis of dementia with Lewy bodies.// Neurology. -2001. -V. 57. P. 1497−1499.
- McKeith I., Del Ser T., Spano P., et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study.// Lancet. 2000. — V. 356. — P. 2031−2036.
- McKeith I., Perry E.C., Perry R.H. Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consorcium on dementia with Lewy bodies.//Neurology. 1999. — V. 53. — P. 902−905.
- McKeith IG, Del Ser T, Spano PF, et al: Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000- 356:2031−2036
- McKeith IG, Galasko D, Kosaka K, et al: Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996- 47:205−218
- McKeith IG, Grace JB, Walker Z, et al: Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. Int J Geriatr Psychiatry 2000- 15:387−392
- McKeith IG, Perry RH, Fairbairn AF, et al: Operational criteria for senile dementia of Lewy body type (SDLT). Psychol Med 1992- 22:911−922
- McKeith IG: Clinical Lewy body syndromes. Ann NY Acad Sci 2000- 920:1−8
- McKenzie I.//Activated microglia in dementia with Lewy bodies.//Neurology. ~V. 55.-P. 132−134.
- McKhann G, Drachman D, Folstein M, et al: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984- 34:939−944
- McLendon B.M., Doraiswamy P.M. Defining meaningful change in Alzheimer’s disease trials: the donepezil experience.// J. Geriatr. Psychiatry Neurol. 1999. — V. 12. — P. 39−48.
- McLennan W.J., Hall M.R., Timothy J. Postural hypotension in old age: is it a disorder of the nervous system or of blood vessels?// Age and Ageing. 1980. — V. 9. —P. 25−32.
- McShane R.H., Nagy Z., Esiri M. Anosmia in dementia is associated with Lewy bodies rather than Alzheimer’s pathology.// J. Neurol. Neurosurg. Psychiatry. 2001. — V. 70.-P. 739−743.
- Mega M.S., Masterman D.L., Benson D.F., et al. Dementia with Lewy bodies: reliability and validity of clinical and pathologic criteria.//Neurology. -1996.-V. 47.-P. 1403−1409.
- Minoshima S., Foster N.L., Sima A. A., et al. Alzheimer’s disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation.// Ann. Neurol. 2001.-V. 50.-P. 358−365.
- Mitnitski A., Graham J.E., Mogilner A.J., et al. The rate of decline in function in Alzheimer’s disease and other s.// J. Gerontol. Med. Sei. 1999. — V. 54. — P. M65-M69.
- Morris J.C., Cyrus P.A., Orazem J., et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer’s disease.// Neurology. -1998.-V. 50.-P. 1222−1230.
- Muller T., Eising E., Kuhn W., et al. Delayed motor response correlates with striatal degeneration in Parkinson’s disease.// Acta Neurol. Scand. 1999. — V. 100. — P. 227−230.
- Muller T., Farahati J., Kuhn W., et al. 123Ibeta-CIT SPECT visualizes dopamine transporter loss in de novo parkinsonian patients.// Eur. Neurol. 1998. — V. 39. — P. 4448.
- Nicholl CG, Lynch S, Kelly CA, et al: The Cognitive Drug Research computerised assessment system in the evaluation of early dementia—is speed of the essence? Int J Geriatr Psychiatry 1995- 10:199−206
- O’Brien J.T., Paling S., Barber R., et al. Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD, and vascular dementia.// Neurology. -2001. -V. 56. P.1386−1388.
- Olson E.J., Boeve B.F., Silber M.H. Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases.// Brain. -2000. V. 123. -N. 2.-P. 331−339.
- Orimo S., Ozawa E., Nakada S., et al. J-metajodbenzylguanidine myocardial scintigraphy in Parkinson’s disease.//! Neurol. Neurosurg. Psychiatry. 1999. — V. 67. — P. 183−194.
- Orth M., Schapira A.H. Mitochondria and degenerative disorders.// Am. J. Med. Genet. 2002. — V. 106. — P. 27−36.
- Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 1962- 10:799−812
- Pakiam A.S., Bergeron C., Lang A.E. Diffuse Lewy body disease presenting as multiple system atrophy.// Can. J. Neurol. Sei. 1999. — V. 26. — P. 127−131.
- Pantev M., Ritter R., Gortelmeyer R. Clinical and behavioral evaluation in long- term care patients with mild to moderate dementia under Memantine treatment. //Zeitsch. Gerontopsychol Psychiatr. -1993. -V.6. -P. 103−117.
- Papka M., Rubio A., Schiffer R.B., et al. Lewy body disease: can we diagnose it?//J. Neuropsychiatry. Clin. Neurosci. 1998. -V. 10. — P. 405−412.
- Parkinson J. An essay on the shaking palsy. Chapter 4. London: Sherwood, Neely, and Jones, 1817.
- Parsons C.G., Danysz W., Quack G. Glutamate in CNS disorders as a target for drug development: an update. //Drug News Perspect. -1998. -V. 11. N.9. -P.523−569.
- Parsons C.G., Danysz W., Quack G. Memantine is a clinically well tolerated N- methyl-D-aspartate (NMDA) receptor antagonist a review of preclinical data. //Neuropharmacol. -1999. -V.38. -P.73 5−767.
- Partridge JG, Apparsundaram S, Gerhardt GA, et al: Nicotinic acetylcholine receptors interact with dopamine in induction of striatal long-term depression. J Neurosci 2002- 22:2541−2549
- Pascual-Leone A., Valls-Sole J., Brasil-Neto J.P., et al. Akinesia in Parkinson’s disease. I. Shortening of simple reaction time with focal, single-pulse transcranial magnetic stimulation.//Neurology. 1994. -V. 44. -N. 5. — P. 884−891.
- Pearce J. The Lewy body. J. Neurol. Neurosurg. Psychiatry. — 2001. — V. 71. -P. 214.
- Pellise A., Roig C., Barraquer-Bordas L.I., et al. Abnormal, ubiquitinated cortical neurites in patients with diffuse Lewy body disease.//Neurosci. Lett. -1996. —V. 206. NN. 2−3. -P. 85−88.
- Perry E, Walker M, Grace J, Perry R: Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci 1999- 22:273−280
- Perry EK, Marshall E, Perry RH, et al: Cholinergic and dopaminergic activities in senile dementia of Lewy body type. Alzheimer Dis Assoc Disord 1990- 4:87−96
- Petrella J.R., Coleman R.E., Doraiswamy P.M. Neuroimaging and Early Diagnosis of Alzheimer Disease: A Look to the Future.// Radiology. 2003. — V. 226.-P. 315−336.
- Petrovitch H., White L.R., Izmirilian G., et al. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia Aging Study.//Neurobiol Aging. 2000. — V. 21. — P. 57−62
- Querfurth HW, Allam GJ, Geffroy MA, et al: Acetylcholinesterase inhibition in dementia with Lewy bodies: results of a prospective pilot trial. Dement Geriatr Cogn Disord 2000- 11:314−321
- Reisberg B, Borenstein J, Salob SP, et al: Behavioral symptoms in Alzheimer’s disease: phenomenology and treatment. J Clin Psychiatry 1987- 48(suppl):9−15
- Rogers S.L., Farlow M.R., Doody R.S., et al. A 24-week, double-blind, placebo- controlled trial of donepezil in patients with Alzheimer’s disease.//Neurology. 1998. — V. 50.-P. 136−145.
- Rojas-Fernandez CH: Successful use of donepezil for the treatment of dementia with Lewy bodies. Ann Pharmacother 2001- 35:202−205
- Rosier M., Anand R., Cicin-Sain A., et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial.//BMJ. 1999. -V. 318. — P. 633−638.
- Ruter E., Glaser A., Bleich S. et al. A prospective PMS study to validate the sensitivity for change of the D-Scale in advanced stages of dementia using the NMD A- antagonist memantine. //Pharmacopsychiatr. -2000. -V.33. -P. 103−108.
- Sahgal A., Galloway P.H., McKeith I., et al. A comparative study of attentional deficits in senile dementias of Alzheimer and Lewy body types.// Dementia. 1992. — V. 3. — P. 350−354.
- Sahgal A., Galloway P.H., McKeith I., et al. Matching-to-sample deficits in patients with senile dementias of the Alzheimer and Lewy body types// Arch. Neurol. 1992.-V. 49.-P. 1043−1046.
- Sakakibara R., Hattori T., Uchiyama T., et al. Videourodynamic and sphincter motor unit potential analyses in Parkinson’s disease and multiple system atrophy.// J. Neurol. Neurosurg. Psychiatry. 2001. — V. 71. -P. 600−606.
- Salmon D.P., Butters N., Chan A.S. The deterioration of semantic memory in Alzheimer’s disease.// Can. J. Exp. Psychol. 1999. — V. 53. — P. 108−116.
- Samuel W, Caligiuri M, Galasko D, et al: Better cognitive and Psychopathologie response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry 2000- 15:794−802
- Scahill R.I., Schott J.M., Stevens J.M., et al. Mapping the evolution of regional atrophy in Alzheimer’s disease: unbiased analysis of fluid-registered serial MRI.// Proc. Natl. Acad. Sei. USA. 2002. — V. 99. — P. 4703−4707.
- Schneider E. Autonome Storungen bei der Parkinson-Krankheit und deren Behandlung.//Nervenarzt. 1999. — V. 70. — Suppl. 1. — S. 26−34.
- Schon E.A., Manfredi G. Neuronal degeneration and mitochondrial dysfunction.// J. Clin. Invest. 2003. — V. 111. — P. 303−312.
- Schultz D.W., Lennox G.G., Ironside J.W. Behavioural disturbance and visual hallucinations in a 78 year old man.// J. Neurol. Neurosurg. Psychiatry. -1998.-V. 65.-P. 933−938.
- Sechi G, Agnetti V, Masuri R, et al: Risperidone, neuroleptic malignant syndrome and probable dementia with Lewy bodies. Prog Neuropsychopharmacol Biol Psychiatry 2000- 24:1043−1051
- Seibyl J.P., Marek K.L., Quinlan D., et al. Decreased single-photon emission computed tomographic Ibeta-CIT striatal uptake correlates withsymptom severity in Parkinson’s disease.// Ann. Neurol. 1995. — V. 38. — P. 589 598.
- Senard J.M., Rai S., Lapeyre-Mestre ML, et al. Prevalence of orthostatic hypotension in Parkinson’s disease.//J. Neurol. Neurosurg. Psychiatry. 1997, — V. 63. — P. 584−589.
- Shea C, MacKnight C, Rockwood K: Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. Int Psychogeriatr 1998- 10:229 238
- Shimamoto H., Morimitsu H., Sugita S., et al. Motor evoked potentials of transcranial magnetic stimulation for Parkinson’s disease.// No To Shinkei. 1996. — V. 48.-N. 9.-P. 825−829.
- Shimamoto H., Morimitsu H., Sugita S., et al. Therapeutic effect of repetitive transcranial magnetic stimulation in Parkinson’s disease.// Rinsho Shinkeigaku. 1999. — V. 39.-N. 12.-P. 1264−1267.
- Shimomura T., Mori E., Yamashita H., et al. Cognitive loss in dementia with Lewy bodies and Alzheimer’s disease.// Arch. Neurol. 1998. — V. 55. — P. 1547−1552
- Shiozaki K, Iseki E, Uchiyama H, et al: Alterations of muscarinic acetylcholine receptor subtypes in diffuse Lewy body disease: relation to Alzheimer’s disease. J Neurol Neurosurg Psychiatry 1999- 67:209−213
- Shiozaki K., Iseki E., Uchiyama H., et al. Alterations of muscarinic acetylcholine receptor subtypes in diffuse Lewy body disease: relation to Alzheimer’s disease.// J. Neurol. Neurosurg. Psychiatry. 1999. — V. 67. — P. 209 213.
- Shoji M., Harigaya Y., Sasaki A., et al. Accumulation of NACP/fX-synuclein in Lewy body disease and multiple system atrophy.// J. Neurol. Neurosurg. Psychiatry. -- V. 68. P. 605−608.
- Silverman D.H., Small G.W., Chang C.Y., et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome.// JAMA. -- V. 286. P. 2120−2127.
- Simard M, van Reekum R, Cohen T: Review of cognitive and behavioral symptoms in dementia with Lewy bodies. J Neuropsychiatry Clin Neurosci 2000- 12:425−450
- Simard M, van Reekum R, Myran D, et al: Differential memory impairment in dementia with Lewy bodies and Alzheimer’s disease. Brain Cogn 2002- 49:244 249
- Simard M, van Reekum R, Suvajac B: Improving cognition, behavior and function, and slowing disease progression of Alzheimer’s disease: a review. Clin Geriatr 2000- 8:32−58
- Simard M, van Reekum R: Memory assessment in studies of cognition-enhancing drugs for Alzheimer’s disease. Drugs Aging 1999- 14:197−230
- Simard M: Management of psychosis in dementia with Lewy bodies. J Geriatr Care 2002- 1:245−252
- Simard M: Mini-Mental-State-Examination: strengths and weaknesses of a cognitive instrument. Canadian Alzheimer’s Disease Rev 1998- 2:10−12
- Simpson PM, Surmon DJ, Wesnes KA, et al: The Cognitive Drug Research computerised assessment system for demented patients: a validation study. Int J Geriatr Psychiatry 1991- 6:95−102
- Skjerve A, Nygaard HA: Improvement in sundowning in dementia with Lewy bodies after treatment with donepezil. Int J Geriatr Psychiatry 2000- 15:1147−1151
- Smith S.A., Fasler J.J. Age-related changes in autonomic function: relationship with postural hypotension.// Age and Ageing. 1983. — V. 12. — P. 206−210.
- Tariot P.N., Solomon P.R., Morris J.C., et al. A 5-month, randomized, placebo- controlled trial of galantamine in AD.// Neurology. 2000. — V. 54. — P. 2269−2276.
- Teng EL, Chui HC: The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry 1987- 48:314−318
- Thaisetthawatkul P., Boeve B.F., Benarroch E.E., et al. Autonomic dysfunction in dementia with Lewy bodies.// Neurology. 2004. — V. 62. — P. 1804−1809.
- Thompson P.M., Hayashi K.M., De Zubicaray G., et al. Dynamics of Gray Matter Loss in Alzheimer’s Disease.// The Journal of Neuroscience. 2003. — V. 23. N. 3. — P. 994−998.
- Tiraboschi P, Hansen LA, Alford M, et al: Early and widespread cholinergic losses differentiate dementia with Lewy bodies from Alzheimer’s disease. Arch Gen Psychiatry 2002- 59:946−951 Abstract/Free Full Text.
- Tiraboschi P., Hansen L., Alford M. Cholinergic dysfunction in diseases with Lewy bodies.// Neurology. 2000. — V. 54. — P. 407.
- Tiraboschi P., Hansen L., Alford M., et al. Early and Widespread Cholinergic Losses Differentiate Dementia With Lewy Bodies From Alzheimer Disease.// Arch. Gen. Psychiatry. 2002. — V. 59. — P. 946−951.
- Tissingh G., Booij J., Bergmans P., et al. Iodine-123-N-omega-fluoropropyl- 2beta-carbomethoxy-3beta-(4-iod ophenyl) tropane SPECT in healthy controls and early- stage, drug-naive Parkinson’s disease.// J. Nucl. Med. -1998.-V. 39.-P. 1143−1148.
- Tretiakoff C. Contributions a l’etude de l’anatomie pathologique du locus niger de Soemmering avec quelques deductions relatives a la pathogenie des troubles de tonus musculaire et de la maladie de Parkinson.//Paris: Thesis. 1919.
- Treves T.A., Verchovsky R., Klimovitsky S., et al. Recruitment rate to drug trials for dementia of the Alzheimer type.// Alzheimer. Dis. Assoc. Disord. 2000. -V. 14.-P. 209−211.
- Turner R.S., D’Amato C.J., Chervin R.D. The pathology of REM sleep behavior disorder with comorbid Lewy body dementia.// Neurology. 2000. — V. 55. — P. 17 301 732.
- Valls-Sole J., Pascual-Leone A., Brasil-Neto J.P., et al. Abnormal facilitation of the response to transcranial magnetic stimulation in patients with Parkinson’s disease.// Neurology. 1994. -V. 44. -N. 4. — P. 735−741.
- Valzania F., Strafella A.P., Quatrale R., et al. Motor evoked responses to paired cortical magnetic stimulation in Parkinson’s disease.// Electroencephalogr. Clin. Neurophysiol. 1997. -V. 105. -N. 1. — P. 37−43.
- Van Dyck C.H., Newhouse P., Falk W.E., et al. Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study Group.// Arch. Gen. Psychiatry. -2000.-V. 57.-P. 157−164.
- Van Hoesen G., Augustinack J., Redman S. Ventromedial Temporal Lobe Pathology in Dementia, Brain Trauma, and Schizophrenia.//Ann. NY. Acad. Sci. -1999. V. 877. -N. 1. — P. 575 — 594
- Verghese J., Crystal H.A., Dickson D.W., et al. Validity of clinical criteria for the diagnosis of dementia with Lewy bodies.// Neurology. 1999. — V. 53. — P. 1974−1982.
- Walker MP, Ayre GA, Cummings JL, et al: The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale: two methods to assess fluctuating confusion in dementia. Br J Psychiatry 2000- 177:252−256
- Walker Z, Grace J, Overshot R, et al: Olanzapine in dementia with Lewy bodies: a clinical study. Int J Geriatr Psychiatry 1999- 14:459166
- Walker Z., Allen R., Shergill S., et al. Neuropsychological performance in Lewy body dementia and Alzheimer’s disease.// Br. J. Psychiatry. 1997. — V. 170. -P. 156 158.
- Walker Z., Costa D.C., Janssen A.G., et al. Dementia with Lewy bodies: a1 O’Xstudy of post-synaptic dopaminergic receptors with 'ZJI-IBZM SPET.// Eur. J. Nucl. Med. 1997.-V. 24.-P. 609−614.
- Walker Z., Costa D.C., Walker R.W., et al. Differentiation of dementia with Lewy bodies from Alzheimer’s disease using a dopaminergic presynaptic ligand.// J. Neurol. Neurosurg. Psychiatry. 2002. -V. 73. — P. 134−140.
- Walters R., Fox N.C., Schott J.M., et al. Transient ischaemic attacks are associated with increased rates of global cerebral atrophy.// J. Neurol. Neurosurg. and Psychiatry. 2003. — V. 74. — P. 213−216.
- Watanabe H., Ieda T., Katayama T., et al. Cardiac 123-J-meta-ioobenzylguanidine (MIBG) uptake in dementia with Lewy bodies- comparison with Alzheimer’s disease.//Neurol. Neurosurg. Psychiatry. 2001. — V. 70. — P. 781−783.
- Weiner M.F., Risser R.C., Cullum C.M., et al. Alzheimer’s disease and its Lewy body variant: a clinical analysis of postmortem verified cases.//Am. J. Psychiatry. 1996.-V. 153.-N. 10.-P. 1269−1273.
- Wenning G.K., Donnemiller E., Granata R., et al. 123I-beta-CIT and 123I-IBZM- SPECT scanning in levodopa-naive Parkinson’s disease.// Mov. Disord. -1998.-V. 13.-P. 438−445.